公开(公告)号：US11873290B2

公开(公告)日：2024-01-16

申请号：US17345909

申请日：2021-06-11

Applicant: Edgewise Therapeutics, Inc.

Inventor： Kevin Hunt ,  Kevin Koch ,  Alan Russell ,  Stephen Schlachter ,  Paul Winship ,  Chris Steele

IPC: C07D401/14 ,  C07D405/14 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06 ,  C07D417/14

CPC classification number: C07D401/14 ,  C07D405/14 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06 ,  C07D417/14

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-α.

公开(公告)号：US20250026740A1

公开(公告)日：2025-01-23

申请号：US18882644

申请日：2024-09-11

Applicant: Edgewise Therapeutics, Inc.

Inventor： Natalie Anne Hawryluk ,  Stephen Thomas Schlachter ,  Kevin Koch ,  Michael Joseph Luzzio ,  Alan James Russell ,  Marc Justin Evanchik ,  Carlos Luis Del Rio

IPC: C07D405/12 ,  A61K31/4353 ,  A61K31/506 ,  C07D221/04 ,  C07D401/12

Abstract: The present disclosure generally relates to substituted quinolinone amide compounds or salts of Formula (I), (II-A), (IV), or (III) and pharmaceutical compositions thereof. The substituted quinolinone amide compounds or salts of Formula (I), (II-A), (IV), or (III) disclosed herein may be used to treat or prevent cardiac disease in an individual in need thereof.

公开(公告)号：US20250026726A1

公开(公告)日：2025-01-23

申请号：US18882652

申请日：2024-09-11

Applicant: Edgewise Therapeutics, Inc.

Inventor： Natalie Anne Hawryluk ,  Stephen Thomas Schlachter ,  Kevin Koch ,  Michael Joseph Luzzio ,  Michael Mark DuVall ,  Alan James Russell ,  Marc Justin Evanchik

IPC: C07D239/96 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048

Abstract: Provided are quinazolinone dione compounds for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction.

公开(公告)号：US20230159513A1

公开(公告)日：2023-05-25

申请号：US18053318

申请日：2022-11-07

Applicant: Edgewise Therapeutics, Inc.

Inventor： Kevin Koch ,  Kevin Hunt ,  Stephen Schlachter ,  Alan Russell

IPC: C07D413/14 ,  C07D413/04 ,  C07D417/04 ,  C07D417/14 ,  C07D409/04 ,  C07D405/04 ,  C07D403/04 ,  C07D409/14

CPC classification number: C07D413/14 ,  C07D413/04 ,  C07D417/04 ,  C07D417/14 ,  C07D409/04 ,  C07D405/04 ,  C07D403/04 ,  C07D409/14

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-α.

公开(公告)号：US12202819B2

公开(公告)日：2025-01-21

申请号：US18460464

申请日：2023-09-01

Applicant: Edgewise Therapeutics, Inc.

Inventor： Kevin Hunt ,  Kevin Koch ,  Alan Russell ,  Stephen Schlachter ,  Paul Winship ,  Chris Steele

IPC: C07D401/14 ,  C07D405/14 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06 ,  C07D417/14

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-α.

公开(公告)号：US20240336609A1

公开(公告)日：2024-10-10

申请号：US18666699

申请日：2024-05-16

Applicant: Edgewise Therapeutics, Inc.

Inventor： Kevin Koch ,  Natalie Anne Hawryluk ,  Stephen Thomas Schlachter ,  Alan James Russell

IPC: C07D417/14 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/501 ,  A61K31/5377 ,  C07D417/04

CPC classification number: C07D417/14 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/501 ,  A61K31/5377 ,  C07D417/04

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-α.

公开(公告)号：US20240025879A1

公开(公告)日：2024-01-25

申请号：US18460464

申请日：2023-09-01

Applicant: Edgewise Therapeutics, Inc.

Inventor： Kevin Hunt ,  Kevin Koch ,  Alan Russell ,  Stephen Schlachter ,  Paul Winship ,  Chris Steele

IPC: C07D401/14 ,  C07D405/14 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06 ,  C07D417/14

CPC classification number: C07D401/14 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  C07D417/06 ,  C07D413/06

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-α.

公开(公告)号：US20230150977A1

公开(公告)日：2023-05-18

申请号：US18053326

申请日：2022-11-07

Applicant: Edgewise Therapeutics, Inc.

Inventor： Kevin Koch ,  Kevin Hunt ,  Stephen Schlachter ,  Alan Russell

IPC: C07D403/04 ,  C07D401/14

CPC classification number: C07D403/04 ,  C07D401/14

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-α.

公开(公告)号：US20220106291A1

公开(公告)日：2022-04-07

申请号：US17345909

申请日：2021-06-11

Applicant: Edgewise Therapeutics, Inc.

Inventor： Kevin Hunt ,  Kevin Koch ,  Alan Russell ,  Stephen Schlachter ,  Paul Winship ,  Chris Steele

IPC: C07D401/14 ,  C07D405/14 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06 ,  C07D417/14

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-α.

公开(公告)号：US12012395B2

公开(公告)日：2024-06-18

申请号：US17345909

申请日：2021-06-11

Applicant: Edgewise Therapeutics, Inc.

Inventor： Kevin Hunt ,  Kevin Koch ,  Alan Russell ,  Stephen Schlachter ,  Paul Winship ,  Chris Steele

IPC: C07D401/14 ,  C07D405/14 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06 ,  C07D417/14

CPC classification number: C07D401/14 ,  C07D405/14 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06 ,  C07D417/14

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-α.